Table 2.
Comparison of Clinical and Instrumental Characteristics at Enrollment of AR‐DCM and Non–AR‐DCM Patients
| Baseline Characteristics | AR‐DCM (n=109) | Non–AR‐DCM (n=176) | P Valuea |
|---|---|---|---|
| Male sex, n (%) | 76 (69.7) | 126 (71.6) | 0.736 |
| Age at diagnosis, y | 41±13 | 41±14 | 0.955 |
| LVEDD, mm | 66±10 | 65±11 | 0.476 |
| LVEF, % | 34±11 | 32±14 | 0.425 |
| Complete LBBB, n (%) | 22 (20.2) | 47 (26.7) | 0.222 |
| Complete RBBB, n (%) | 4 (3.7) | 7 (4) | 1.000 |
| Inverted T waves in leads V2 to V3, n (%) | 2 (1.8) | 7 (4) | 0.490 |
| QRS >110 ms in leads V1 to V3, n (%) | 36 (33) | 66 (37.5) | 0.468 |
| Family history of SCD/SVT/VF, n (%) | 11 (10.1) | 14 (7.9) | 0.535 |
| β‐Blocker therapy, n (%) | 99 (90.8) | 153 (86.9) | 0.527 |
| ACEI therapy, n (%) | 88 (80.7) | 138 (78.4) | 0.843 |
AR‐DCM indicates arrhythmogenic dilated cardiomyopathy; LBBB, left bundle branch block; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; RBBB, right bundle branch block; SCD/SVT/VF, sudden cardiac death, sustained ventricular tachycardia, and ventricular fibrillation; ACEI, angiotensin‐converting enzyme inhibitor.
a
Between groups.